Of the different disease subtypes, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) tumors are the most common forms of breast cancer which are potentially sensitive to endocrine therapy (ET) [2, 3]. This evidence concerns the gene ERBB2 and breast cancer.